The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
BUSINESS
Nihon Chouzai Launches Drug Information Service with Standard Formulary Including Few New Meds
Major dispensing pharmacy chain Nihon Chouzai has launched an online platform, dubbed FINDAT, to help medical institutions select medicines by offering a standard formulary and drug reviews. While the formulary is not publicly disclosed, Jiho has learned that few innovative…
To read the full story
Related Article
- Nihon Chouzai Shuts Down FINDAT Formulary Biz amid Tepid Demand
August 28, 2025
- Nihon Chouzai’s Standard Formulary Service Fully Up and Running
October 5, 2020
- Nihon Chouzai’s Standard Formulary Service Expands to 17 Therapeutic Classes, Monitor Hospitals Moving to Craft Own Lists
September 11, 2020
BUSINESS
- iPark Institute to Launch AI-Based Platform to Link Investors with Startups
January 16, 2026
- Acromegaly Drug Palsonify Meets Primary Endpoint in Japan PII/PIII Trial
January 16, 2026
- Tanabe’s EPP/XLP Drug Hits Main Goals in PIII, Weighs Launch Strategy
January 16, 2026
- Forxiga Generics Reach 11% Share in First Month: Intage
January 16, 2026
- Takeda to Halt Sales of Cell Therapy Alofisel in Japan
January 15, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…